Feedback / Questions
coramitug (NN6019) - Novo Nordisk
https://ir.prothena.com/investors/press-releases/news-details/2025/Prothena-Announces-that-Novo-Nordisk-Will-Advance-Coramitug-Formerly-PRX004-into-Phase-3-Development-for-ATTR-Amyloidosis-with-Cardiomyopathy/default.aspx
Aug 6, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next